$0.83
AEON Biopharma postponed its planned initial public offering as the stock market volatility continues to impact the IPO landscape.
We'll update this page as new information becomes available.
Our top picks for where to buy AEON Biopharma stock
How to buy AEON Biopharma stock
- Choose a stock trading platform. Use our comparison table
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – AEON. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy AEON Biopharma stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
AEON Biopharma stock price (NYSE MKT: AEON)
Use our graph to track the performance of AEON stocks over time.AEON Biopharma shares at a glance
Latest market close | $0.84 |
---|---|
52-week range | $0.80 - $17.17 |
50-day moving average | $1.38 |
200-day moving average | $5.33 |
Wall St. target price | $5.00 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | $-0.17 |
Is it a good time to buy AEON Biopharma stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
AEON Biopharma price performance over time
Historical closes compared with the close of $0.842 from 2024-09-03
1 week (2024-08-29) | -11.23% |
---|---|
1 month (2024-08-05) | -17.45% |
3 months (2024-06-05) | -45.68% |
6 months (2024-03-05) | -92.71% |
1 year (2023-09-01) | N/A |
---|---|
2 years (2022-09-01) | N/A |
3 years (2021-09-01) | N/A |
5 years (2019-09-01) | N/A |
AEON Biopharma financials
Gross profit TTM | $0 |
---|---|
Return on assets TTM | -597.69% |
Return on equity TTM | 0% |
Profit margin | 0% |
Book value | $-0.71 |
Market Capitalization | $32.9 million |
TTM: trailing 12 months
AEON Biopharma share dividends
We're not expecting AEON Biopharma to pay a dividend over the next 12 months.
You may also wish to consider:
- Pfizer (PFE.US) (5.79% forward annual dividend yield)
AEON Biopharma share price volatility
Over the last 12 months, AEON Biopharma's shares have ranged in value from as little as $0.8 up to $17.17. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while AEON Biopharma's is 0.422. This would suggest that AEON Biopharma's shares are less volatile than average (for this exchange).
To put AEON Biopharma's beta into context you can compare it against those of similar companies.
- Revance The (RVNC.US): 0.994
- Pfizer (PFE.US): 0.633
- Moderna (MRNA.US): 1.662
AEON Biopharma overview
AEON Biopharma, Inc. , a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of both chronic and episodic migraine, as well as develops ABP-450 for the treatment of gastroparesis and posttraumatic stress disorder. The company is based in Irvine, California. .
Frequently asked questions
nullWhat percentage of AEON Biopharma is owned by insiders or institutions?
Currently 34.099% of AEON Biopharma shares are held by insiders and 23.873% by institutions. How many people work for AEON Biopharma?
Latest data suggests 5 work at AEON Biopharma. When does the fiscal year end for AEON Biopharma?
AEON Biopharma's fiscal year ends in December. Where is AEON Biopharma based?
AEON Biopharma's address is: 5 Park Plaza, Irvine, CA, United States, 92614 What is AEON Biopharma's ISIN number?
AEON Biopharma's international securities identification number is: US00775E1029
More guides on Finder
-
Options profit calculator
Use this calculator to quickly see potential outcomes of your options trades.
-
Best options trading platforms of 2024
SoFi, Robinhood, Tastytrade, Webull, Interactive Brokers, E*TRADE, eToro and others top our list for the best options trading platforms.
-
What is a covered call?
A covered call is an options trading strategy that allows you to generate income from stocks you already own.
-
GSD Capital review 2024
A look at GSD Capital’s highlights, limitations, fees and investment strategies.
-
Today’s best brokerage account bonuses [Signup and transfer promos]
Explore the best bonuses for opening a new brokerage account.
-
10 E*TRADE competitors worth your time
Looking for a discount broker like E*TRADE that offers something different? Here are some of the top alternatives to consider.
-
Charles Schwab vs. Fidelity
Charles Schwab and Fidelity are two powerhouse trading platforms for beginner and advanced investors.
-
Interactive Brokers review 2024: Tailored trading and investing
Interactive Brokers has advanced charting tools but a high net requirement to qualify.
-
Top 15 tech stocks to invest in for 2024
Discover the top tech stocks poised to lead innovation and offer substantial growth opportunities.
-
Wealthfront review: Low-cost automated and DIY investing
Learn about Wealthfront’s automated investing tools and services to see if it’s the right platform for you.
Ask a question